J. Goldman & CO LP Nektar Therapeutics Call Options Transaction History

J. Goldman & CO LP

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $693,750 - $1.57 Million	-15,000 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $9.47 Million - $17.9 Million	-165,000 Reduced 91.67%	15,000 $1.59 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $3.2 Million - $4.32 Million	180,000	180,000 $4.32 Million

126

109M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.